These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1835849)

  • 1. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
    Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG
    Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
    Sharma SK; Bagshawe KD; Springer CJ; Burke PJ; Rogers GT; Boden JA; Antoniw P; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):225-31. PubMed ID: 1813212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
    Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
    J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of carboxypeptidase G2: antibody conjugates as anti-tumour agents. II. In vivo localising and clearance properties in a choriocarcinoma model.
    Melton RG; Searle F; Sherwood RF; Bagshawe KD; Boden JA
    Br J Cancer; 1990 Mar; 61(3):420-4. PubMed ID: 2328209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
    Springer CJ; Niculescu-Duvaz I; Pedley RB
    J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
    Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF
    Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
    Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
    J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
    Sharma SK; Boden JA; Springer CJ; Burke PJ; Bagshawe KD
    Cell Biophys; 1994; 24-25():219-28. PubMed ID: 7736526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
    Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
    Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
    Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
    Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
    Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.